(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.

Related Links:

Pediatric Blood&Cancer, EarlyView.

Conclusion This is the first attempt to provide a glimpse on the pattern and distribution of HMs among AYA in Bangladesh. Future studies are essential to get a better insight on the epidemiology, biology, potential risk factors and treatment outcomes for the AYA age group.

Source: Cancer EpidemiologyCategory: Cancer & Oncology Source Type: research

BOSTON (CBS) — The Dana Farber Cancer Institute and Boston Children’s Hospital will work to fight cancer in a new way thanks to a new treatment approved by the FDA.
CAR-T therapy is for kids and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL).
“It’s really an entirely new type of therapy, an entirely new way to fight cancer,” said Dr. Lewis Silverman, the Clinical Director of the Pediatric Hematologic Malignancies Center.
Chemotherapy drugs attack dividing cells but are not specific to cancer cells, unlike this new treatment, according to Silverman.

ConclusionsErwinia asparaginase 25,000 IU/m2 per dose × six intramuscular administrations in 2 weeks was well tolerated, pharmacologically efficacious, and safe in Japanese patients with ALL/lymphoblastic lymphoma.

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors: Tags: Research Article Source Type: research

Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for

Source: PediatricEducation.orgCategory: Pediatrics Authors: Tags: Uncategorized Source Type: news

CONCLUSIONSAlthough survival for children and AYAs with ALL, AML, and HL has improved over the past 4 decades, differences persist between black, white, and Hispanic children and AYAs; survival disparities between black and white children with ALL have been nearly eliminated. Strategies aimed at identifying causality and reducing disparities are warranted. Cancer 2016. © 2016 American Cancer Society.

Source: CancerCategory: Cancer & Oncology Authors: Tags: Original Article Source Type: research

Over 70,000 adolescent and young adults (AYA) aged 15 to 39 years are diagnosed with cancer each year in the US. The National Cancer Institute (NCI) has identified AYA cancer patients as a unique population. The most common cancers in this age group include tumors typically seen in pediatric patients such as acute lymphoblastic leukemia (ALL) and brain tumors, as well as cancers more typically seen in adult patients such as breast cancer and melanoma. In addition, some cancers have their highest incidence in AYA patients, such as Hodgkin Lymphoma, testicular cancer, and bone tumors. AYA patients face…

Conclusion Insurance status and marriage did not influence outcomes for AYA with ALL, suggesting that intrinsic differences in disease and disease-specific therapies are more important than social issues. Micro-Abstract Outcomes for adolescents and young adults with acute lymphoblastic leukemia are worse when treated with adult rather than pediatric protocols; one criticism is that this may be due to “emancipation” of young adults. Population based review did not show marital and insurance status to be predictive of medial overall survival while age was.

CONCLUSION: Insurance status and marriage did not influence outcomes for AYA with ALL, suggesting that intrinsic differences in disease and disease-specific therapies are more important than social issues.
PMID: 25592548 [PubMed – as supplied by publisher]

Source: Clinical Lymphoma and MyelomaCategory: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image